

A comparison of dicarbonyl stress and advanced glycation endproducts in lifelong endurance athletes *versus* sedentary controls

Martijn F.H. Maessen MSc ^a

Casper G. Schalkwijk PhD ^b

Rebecca J.H.M. Verheggen MSc, MD ^a

Vincent L. Aengevaeren MSc, MD ^a

Maria T.E. Hopman MD, PhD ^a

Thijs M.H. Eijsvogels PhD ^{a,c}

Affiliations:

^a Department of Physiology, Radboud university medical center, Nijmegen, The Netherlands.

^b Department of Internal Medicine, CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, The Netherlands.

^c Research Institute for Sports and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.

Total word count: **3159**

Word count abstract: **250**

Total number of Figures: **1**

Total number of Tables: **2**

Reprints and correspondence:

Dr. Thijs Eijsvogels PhD, Dept. of Physiology (392), Radboud university medical center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: Thijs.Eijsvogels@radboudumc.nl.

Tel. (+31) (0)24 36 14200 Fax. (+31) (0)24 36 68340

ABSTRACT

Objectives. Dicarbonyl stress and high concentrations of advanced glycation endproducts (AGEs) relate to an elevated risk for cardiovascular diseases (CVD). Exercise training lowers the risk for future CVD. We tested the hypothesis that lifelong endurance athletes have lower dicarbonyl stress and AGEs compared to sedentary controls and that these differences relate to a better cardiovascular health profile. **Design.** Cross-sectional study

Methods. We included 18 lifelong endurance athletes (ATH, 61 ± 7 years) and 18 sedentary controls (SED, 58 ± 7 years) and measured circulating glyoxal (GO), methylglyoxal (MGO) and 3-deoxyglucosone (3DG) as markers of dicarbonyl stress. Furthermore, we measured serum levels of protein-bound AGEs N^{ϵ} -(carboxymethyl)lysine (CML), N^{ϵ} -(carboxyethyl)lysine (CEL), methylglyoxal-derived hydroimidazolone-1 (MG-H1), and pentosidine. Additionally, we measured cardiorespiratory fitness (VO_{2peak}) and cardiovascular health markers.

Results. ATH had lower concentrations of MGO (196 [180-246] vs. 242 [207-292] nmol/mmol lysine, $P=0.043$) and 3DG (927 [868-972] vs. 1061 [982-1114] nmol/mmol lysine, $P<0.01$), but no GO compared to SED. ATH demonstrated higher concentrations CML and CEL compared to SED. Pentosidine did not differ across groups and MG-H1 was significantly lower in ATH compared to SED. Concentrations of MGO en 3DG were inversely correlated with cardiovascular health markers, whereas CML and CEL were positively correlated with VO_{2peak} and cardiovascular health markers.

Conclusion. Lifelong exercise training relates to lower dicarbonyl stress (MGO and 3DG) and the AGE MG-H1. The underlying mechanism and (clinical) relevance of higher CML and CEL concentrations among lifelong athletes warrants future research, since it conflicts with the idea that higher AGE concentrations relate to poor cardiovascular health outcomes.

Key words: oxidative stress; cardiovascular disease; physical activity; exercise physiology

Introduction

Advanced glycation endproducts (AGEs) are a complex group of modified proteins or lipids that are formed by a process of non-enzymatically glycation and oxidation. AGEs formation is a slow process (*i.e.*, weeks to months) and depends on the extent of oxidative stress, degree of hyperglycemia, and turnover rate of proteins.^{1, 2} The formation of AGEs is irreversible and AGEs accumulate with increasing age. Highly reactive dicarbonyls (α -oxoaldehydes) are involved in the fast formation of AGEs and accumulation of dicarbonyls is known as dicarbonyl stress.^{1, 2} Dicarbonyls are precursors for AGEs³ and the most important dicarbonyl marker is the highly reactive methylglyoxal (MGO).⁴ Dicarbonyl stress and a high concentration of AGEs are linked to the development of cardiovascular diseases.⁴⁻⁶

Higher levels of circulating AGEs are also related to higher vascular stiffness.⁷⁻⁹ There are several mechanisms proposed how AGEs may affect the vascular wall properties, such as binding to receptor AGEs (RAGEs) and cross-linking matrix proteins in the vessel wall.^{2, 10} AGE-binding to RAGEs leads to an upregulation of inflammation and production of reactive oxygen species.^{11, 12} These processes augment vascular dysfunction and may promote vascular stiffness.^{11, 12} Alternatively, AGEs can also bind to collagen and elastin to form crosslinks with matrix proteins, which promotes vascular stiffness.¹² Strategies to lower the burden of high levels of AGEs may improve cardiovascular health and need to be explored.

Regular exercise training is part of a healthy lifestyle and is an effective strategy to reduce the risk for cardiovascular morbidity and mortality.^{13, 14} Exercise training attenuates the age-associated decline in cardiovascular function,^{15, 16} and improves glucose¹⁷ and lipid metabolism.¹⁸ Findings from animal studies suggest that these health benefits of exercise training may relate to a reduction of dicarbonyl stress and AGEs concentrations.^{19, 20} Clinical studies linking exercise training with dicarbonyl stress or AGEs are, however, sparse and conflicting.²¹⁻²³ A previous study demonstrated that 12 months of tai chi training for 2 sessions/week significantly reduced serum AGEs concentrations in asymptomatic middle-aged adults.²³ However, another study found no effect on serum AGEs concentrations in

middle-aged overweight or obese men after a 3-month aerobic moderate intensity exercise training program²¹. Variation in study outcomes may partially relate to the training duration (3 vs. 12 months), exercise intensity (light vs. moderate), or study population (asymptomatic vs. overweight/obese). Lifelong endurance athletes may provide better insight to what extent exercise is related to attenuated AGEs formation.

Therefore, we tested the hypothesis that lifelong endurance athletes have lower dicarbonyl stress and a lower concentration of AGEs compared to sedentary controls. Additionally, we explored whether lower dicarbonyl stress and lower concentration of AGEs relate to a better cardiovascular health profile.

Methods

Thirty-six male participants aged >45 years were included and stratified into 2 groups based on their lifelong exercise patterns: 1) lifelong endurance athletes (ATH, n=18), 2) sedentary controls (SED, n=18). ATH had to perform ≥ 20 years of endurance exercise training (e.g., running or cycling) for ≥ 4 hours/week, whereas SED had to report ≥ 20 years of habitual physical activity <2 hours/week. Current smokers, participants with a history of diabetes mellitus or cardiovascular disease, or participants not able to perform an incremental maximal cycling test were not included in the study. The Local Committee on Research Involving Human Subjects of the region Arnhem and Nijmegen approved the study. All participants gave their written informed consent prior to study participation.

During this cross-sectional study, participants visited our laboratory on 2 separate days. On day 1, participants were medically screened for eligibility, followed by an incremental maximal cycling test to determine their physical fitness. On day 2, pulse wave velocity was measured as an index of vascular stiffness and blood samples were obtained under fasting conditions. Both testing days were scheduled within a 14-day time-frame, with at least 1 recovery day between measurement day 1 and 2.

A physician medically screened the participants by taking a detailed medical history, physical examination, and 12-lead electrocardiogram. After screening, participants performed an incremental maximal cycling test to determine the cardiorespiratory fitness and peak oxygen uptake ($\text{VO}_{2\text{peak}}$, mLO_2/min). The test took place in a temperature-controlled room (18-19°C) and under the supervision of a physician. Participants cycled with 60-80 rotations per minute while the workload increased with 20 Watt/min for ATH and 10 Watt/min for CON. Heart rate was continuously measured via a 12 lead-electrocardiogram. Oxygen uptake (VO_2 [mL/min]), carbon dioxide output (VCO_2 [mL/min]), and respiratory exchange ratio (RER) were continuously measured via a gas analyser (CPET, Cosmed v9.1b, Rome, Italy). Lactate concentration (mmol/L) was measured (Lactate Pro™ 2, Arkay, type LT-1730, Kyoto, Japan) via a capillary blood sample taken 1.5 minute after cessation of the exercise test. The incremental maximal cycling test was considered successful when 2 of the 4 criteria were met: 1)

RER ≥ 1.05 , II) achievement of at least 85% of age-predicted maximal heart rate ($220 - \text{age}$), III) blood lactate ≥ 6.00 mmol/L, or IV) flattening of VO_2 uptake curve (≤ 150 mL increase during the last minute).^{24, 25}

Lifelong exercise patterns were queried via an exercise history questionnaire, distinguishing 5 age-periods: I) 20-29 years, II) 30-39 years, III) 40-49 years, IV) 50-59 years and V) >60 years. Each category consisted of 2 queries: 1) type of activity (*e.g.*, running, cycling, etc., or nothing) and 2) exercise time (hours) per activity per week. Based on the Compendium of Physical Activities²⁶, the corresponding metabolic equivalent of task (MET) score per exercise activity was determined. Vigorous exercise activities were defined as a MET score >6 . Subsequently, exercise volume (MET-hours/week) was calculated by multiplying exercise time with accompanying MET score. The average exercise time and dose were calculated over the last 2 decades.

Before the second testing day, participants were asked to abstain from I) (vigorous) physical activities for 24 hours, II) caffeine, alcohol, or vitamin supplement intake for at least 18 hours, and III) food intake for ≥ 6 hours. Central and peripheral pulse wave velocity was assessed with a three-lead electrocardiogram and an echo-Doppler ultrasound machine (WakiLoki Doppler, 4 MHz, Atys) at the left carotid artery, right common femoral artery, and radial artery. The distances between sternal notch and site of measurement for the carotid artery and between radial artery and common femoral artery via the umbilicus were measured.²⁷ At least 10 cardiac cycles were recorded for analyses. Based on the R-R interval and onset of the Doppler waveform, central and peripheral pulse wave velocities were calculated in Matlab R2014 (The MathWorks Inc., United States).

Following vascular measurements, a fasting blood sample (8 mL) was obtained from an antecubital vein for the assessment of concentrations of dicarbonyl stress and AGEs. Additionally, lysine and traditional cardiovascular risk factors (total-, high-density lipoproteins [HDL]-, low-density lipoproteins [LDL]-cholesterol, triglycerides, glycated hemoglobin [HbA1C], and glucose) were determined. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated based on

glucose and insulin concentrations ($IR = (\text{fasting insulin [mU/L]} \times \text{fasting glucose [mmol/L]})/22.5$).²⁸

To gain insight in the cardiovascular (risk) profile of ATH and SED, the 10-year CVD risk was calculated via the Framingham Risk Score (FRS).²⁹

For measurement of serum levels of diarbonyl components and AGEs, we used ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS, Waters, Milford Massachusetts, USA). UPLC-MS/MS combines liquid chromatography for separation and tandem mass spectrometry for specific detection.

Whole blood samples in serum-separating tubes were centrifuged after collection (10 min, 4°C, 3,000 g) and supernatant was stored at -80°C until analysis. Serum levels of dicarbonyl compounds glyoxal (GO), MGO, and 3-deoxyglucosone (3DG) were analysed following a previously described protocol.³ Briefly, serum samples were deproteinized using perchloric acid and subsequently derivatized with o-phenylenediamine. GO, MGO, and 3DG concentrations were measured using stable isotope-dilution UPLC-MS/MS (Waters, Milford Massachusetts, USA) with a run-to-run time of 8 min. Intra-run and inter-run variations were 4.3% and 14.3% for GO, 2.9% and 7.3% for MGO, and 2.4% and 12.0% for 3DG, respectively.³

Protein-bound serum AGEs N^ε-(carboxymethyl)lysine (CML), N^ε-(carboxyethyl)lysine (CEL), methylglyoxal-derived hydroimidazolone-1 (MG-H1), and lysine were measured with UPLC-MS/MS (Waters, Milford Massachusetts, USA), as previously described.^{30, 31} Pentosidine was measured with high-performance liquid chromatography and fluorescent detection.³¹ Intra-run and inter-run variations were 2.8% and 7.1% for CML, 3.7% and 6.4% for CEL, 3.7% and 5.1% for MG-H1, and 2.0% and 3.1% for pentosidine.^{30, 31} All serum AGEs were adjusted for lysine concentrations as a marker of total protein concentration.

Participant characteristics were summarized with means and standard deviations or median and interquartile range (IQR), when appropriate. Categorical data were analysed using the *Fisher's exact*

149 test. Parameters were checked for normality using a *Shapiro-Wilk* test and Q-Q plots. Skewed
150 variables were log_e-transformed before statistical analyses were conducted. Differences in participant
151 characteristics, lifelong exercise patterns, and cardiovascular health markers between ATH and SED
152 were analysed using an independent *Student's t* test. As an overall measure of pulse wave velocity, z-
153 scores of central and peripheral pulse wave velocities were averaged. Correlations between markers
154 for dicarbonyl stress or AGEs and markers for cardiovascular health (BMI, pulse wave velocity,
155 cardiorespiratory fitness, Framingham risk score, and glucose metabolism) were evaluated using
156 *Spearman's rank* test. All statistical analyses were performed using SPSS 21.0 software (IBM Corp.
157 Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). Statistical
158 significance was assumed at $p < 0.05$ (two-sided).

Results

Age, height, mean arterial pressure, and smoking history did not differ between groups, but ATH demonstrated a lower body weight and Body Mass Index compared to SED (Table 1). HbA1c, total cholesterol, and glucose concentrations did not differ between groups, but ATH demonstrated a higher HDL cholesterol concentration and lower LDL cholesterol, triglycerides, and HOMA-IR compared to SED (Table 1). The median time between smoking cessation and study participation was 28 years (Q_{25} : 12 to Q_{75} : 40) in ATH *versus* 25 years (Q_{25} : 15 to Q_{75} : 37) in SED ($P=0.78$).

ATH showed a significantly higher weekly exercise time and dose compared to SED (Table 1). ATH mostly performed vigorous-intensity exercise activities (e.g. running or road cycling). We observed a higher VO_{2peak} in ATH (3544 ± 651 mL/min) compared to SED (2843 ± 519 mL/min, $p<0.01$). Likewise, ATH reached a higher power output during the incremental exercise test compared to SED ($p<0.01$, Table 1).

Central pulse wave velocity was significantly lower in ATH (7.0 ± 2.2 m/s) compared to SED (9.2 ± 2.3 m/s, $P<0.01$). Peripheral pulse wave velocity was significantly lower in ATH (8.1 ± 1.5 m/s) compared to SED (9.4 ± 1.6 m/s, $p=0.017$).

MGO (196 [180 - 246] *vs.* 242 [207 - 292] nmol/mmol lysine, $P=0.043$) and 3DG (927 [868 - 972] *vs.* 1061 [982 - 1114] nmol/mmol lysine, $p<0.01$) concentrations were lower in ATH compared to SED (Figure 1). Glyoxal concentrations did not differ between ATH *vs.* SED (314 [202 - 451] *vs.* 342 [266 - 388] nmol/mmol lysine, $p=0.86$, Figure 1).

CML was significantly higher in ATH (80 [73 - 89] nmol/mmol lysine) *vs.* SED (68 [56 - 76] nmol/mmol lysine, $p<0.01$, Figure 2). Similarly, CEL was significantly higher in ATH (35 [28 - 41] nmol/mmol lysine) compared to SED (28 [24 - 34] nmol/mmol lysine, $p=0.035$). Pentosidine (0.63 [0.59 - 0.86] *vs.* 0.56 [0.48 - 0.67] nmol/mmol lysine, $p=0.11$) did not differ between groups (Figure 2).

186 MG-H1 concentration was significantly lower in ATH (363 [288-468] nmol/mmol lysine) compared to
187 SED (460 [340-536] nmol/mmol lysine, $p=0.043$, Figure 2).

188
189 MGO was positively correlated with BMI, central PWV, and FRS. (Table 2). 3DG was negatively
190 correlated with VO_{2peak} , but positively correlated with BMI, central and peripheral PWV, FRS, and
191 glucose (Table 2). GO did not correlate with cardiovascular health parameters (Table 2).

192
193 CML was negatively correlated with BMI and peripheral PWV, but positively correlated with
194 VO_{2peak} . MG-H1 was negatively correlated with VO_{2peak} (Table 2). Pentosidine was negatively
195 correlated with peripheral PWV and glucose (Table 2). CEL did not correlate with cardiovascular
196 health parameters (Table 2).

Discussion

This study aimed to compare markers of dicarbonyl stress and circulating AGEs between lifelong endurance athletes and sedentary controls. MGO and 3DG were significantly lower in ATH compared to SED, and were related to a better cardiovascular health profile. However, we also found that CML and CEL were significantly higher in ATH compared to SED.

The benefits of exercise training on cardiovascular health are indisputable¹⁴⁻¹⁶, but underlying mechanisms explaining the lower risk for cardiovascular events in physically active individuals are not fully understood¹⁶. Our results suggest that benefits of exercise training relate to a lower concentration of MGO and 3DG. These findings are in line with a recent study in rats, which demonstrated that running exercise was associated with a reduction in dicarbonyl stress¹⁹. In general, we found that markers of dicarbonyl stress showed a moderate, yet significant correlation with cardiovascular health or metabolic markers. For example, lower concentration MGO and 3DG were correlated to low Framingham risk score, lower insulin concentration, and better HOMA-IR. Reducing hyperglycaemia and improving insulin sensitivity may be a first step to reduce accumulation of MGO^{4,32} and 3DG³². High levels of dicarbonyl stress, and especially MGO, increase morbidity risk⁴⁻⁶. MGO is highly reactive and is mainly catabolized via glyoxalase I of the glyoxalase system. The activity of the glyoxalase system depends on concentrations of reduced glutathione (GSH)^{4,33}. Biosynthesis of GSH is heavily dependent of the antioxidant response element-nuclear respiratory factor (ARE-Nrf) pathway. Animal and human studies demonstrated that an acute bout of swimming or moderate intensity endurance exercise training upregulate the ARE-Nrf pathway and GSH biosynthesis. This led to the hypothesis that exercise training enhances the glyoxalase system and may lower MGO and MG-H1 concentrations.³⁴ Based on our data, it can be speculated that exercise training possibly lowers the levels of MGO and MG-H1 via an upregulation of the glyoxalase system. Further research is warranted to explore these pathways. Taken together, our data demonstrated that exercise training is related to lower levels of MGO, 3DG, and MG-H1.

In contrast to our hypothesis, we found that 2 of the 4 AGEs (CML and CEL) were significantly higher in ATH, whereas MG-H1 was significantly lower in ATH compared to SED. Although MG-H1 is a AGE, it is produced in a much shorter timeframe and is less stable than CML, CEL or pentosidine.³⁵ MG-H1 may, therefore, better relate to abnormal accumulation of dicarbonyl stress.³⁵ This could explain why MG-H1 showed opposite results compared to the other AGEs, since dicarbonyl stress was lower in ATH compared to SED.

Previous studies indicated that an increase in AGEs concentration relates to poor health outcomes.⁴⁻⁶ Our findings are contradictory to this concept, as we found an inverse relation between circulating CML and pulse wave velocity, BMI, and cardiorespiratory fitness. A potential explanation for this finding could be that exercise enhances collagen turnover rate, which breaks and prevents AGE cross-links in the vessel wall.^{12, 36, 37} This may contribute to higher levels of circulating AGEs, but this hypothesis needs to be reinforced with future studies. Alternatively, a recent animal study demonstrated that a 12-week running exercise training leads to suppressed RAGEs activation in the aorta of aged rats.³⁸ It could be speculated that attenuated RAGEs activity limits the uptake of AGEs from the circulation to the surrounding tissue,³⁹ leading to increased levels of circulating AGEs. Thus, the observation of higher AGEs in lifelong endurance athletes may relate to a higher collagen turnover and/or suppression of RAGEs due to long-term exercise training.

Another possible explanation for the higher AGEs concentrations in ATH vs. SED may relate to the (vigorous) exercise training regimes of our lifelong endurance athletes. Acute exercise induces a transient increase in oxidative stress,⁴⁰ which upregulates the formation of AGEs.^{1, 2} Mice deficient in NADPH (nicotinamide adenine dinucleotide phosphate) oxidase, a pathway involved in the generation of reactive oxygen species, showed an impaired CML generation, which suggests that oxidative stress is a potential stimulus to generate CML.⁴¹ Although the sudden increase in oxidative stress is a necessary stimulus to enhance the anti-oxidative defence mechanism (*i.e.*, glyoxalase system),⁴² it is possible that the formation of AGEs is simultaneously upregulated. The positive relation between exercise dose / time and CML concentrations found in the present study (Table 2) may relate to the

effects of sustained exposure to vigorous exercise training. Hence, lifelong and repetitive exposure to vigorous exercise increases oxidative stress and may boost the accumulation of circulating AGEs in the blood. Future research is warranted to elucidate the underlying mechanisms and (clinical) impact of higher AGEs (CML and CEL) concentrations in athletes, as this observation contradicts with the general believe that high concentrations of circulating AGEs relate to CVD.

This cross-sectional study is inherent to some limitations. First, the comparison between athletes and sedentary individuals does not prove that exercise can attenuate the formation of dicarbonyl stress. A randomized clinical trial would be needed to confirm causation. However, our results indicate that exercise training is related to lower dicarbonyl stress. Unfortunately, we do not have information about the dietary habits of the participants. The absorption, bioavailability, and effects of dietary AGEs are poorly understood in vivo,⁴³ and it could be that diet patterns may contribute to the differences in AGEs between ATH and SED. AGE-rich food intake has been associated with higher levels of serum AGEs, whereas an AGE-restricted diet has been associated with lower serum AGEs.²¹ However, whether food AGEs influence protein bound AGEs, as measured in this study, is not clear. Free AGEs may be relatively quickly absorbed, biotransformed, and excreted. On the other hand, high molecule weight AGEs, such as protein bound AGEs, may not be very extensively absorbed due to insufficient degradation by gastrointestinal enzymes.⁴³ Further research is warranted to establish a direct relation between dietary AGEs and protein-bound AGEs. Finally, all the participants of the study were men and the lifelong athletes performed endurance exercise activities only, which limits the generalizability of the present study.

Conclusion

Findings of the present study indicate that lifelong exercise training is associated with lower dicarbonyl stress (MGO and 3DG), which is related to improved cardiovascular health. Although MG-H1 was lower in lifelong endurance athletes compared to sedentary controls, AGEs concentrations of CML and CEL were significantly higher in athletes compared to sedentary controls. The underlying mechanism and (clinical) relevance of higher CML and CEL concentrations among lifelong athletes

280 warrants future research, since it conflicts with the idea that higher AGEs concentrations relate to poor
281 cardiovascular health.
282

Practical Implications

- Results of our study support the cardiovascular health benefits of lifelong exercise training, as lifelong endurance athletes demonstrated a better cardiovascular risk profile compared to sedentary controls.
- Lifelong exercise training is related to lower dicarbonyl stress, as veteran athletes had lower concentrations of methylglyoxal and 3-deoxyglucosone compared to sedentary controls.
- Lifelong exercise training is related to higher concentrations of advanced glycation endproducts (N^ε-(carboxymethyl)lysine and N^ε-(carboxyethyl)lysine). Although previous studies indicated that higher concentrations of advanced glycation endproducts were associated with adverse outcomes, the clinical significance of our findings in a highly active population is unknown.

Acknowledgements

Dr. TE is financially supported by a European Commission Horizon 2020 grant [Marie Skłodowska-Curie Fellowship]. The remaining authors report no conflicts of interest.

References

1. Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. *Circulation*. 2006; 114(6):597-605.
2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001; 414(6865):813-820.
3. Scheijen JL, Schalkwijk CG. Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen. *Clin Chem Lab Med*. 2014; 52(1):85-91.
4. Maessen DE, Stehouwer CD, Schalkwijk CG. The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases. *Clin Sci (Lond)*. 2015; 128(12):839-861.
5. Hanssen NM, Beulens JW, van Dieren S, et al. Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL). *Diabetes*. 2015; 64(1):257-265.
6. Hanssen NM, Wouters K, Huijberts MS, et al. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. *Eur Heart J*. 2014; 35(17):1137-1146.
7. McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. *Am J Hypertens*. 2007; 20(3):242-247.
8. Semba RD, Najjar SS, Sun K, et al. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. *Am J Hypertens*. 2009; 22(1):74-79.

- 323 9. van Eupen MG, Schram MT, van Sloten TT, et al. Skin Autofluorescence and
324 Pentosidine Are Associated With Aortic Stiffening: The Maastricht Study.
325 *Hypertension*. 2016; 68(4):956-963.
- 326 10. Smit AJ, Lutgers HL. The clinical relevance of advanced glycation endproducts
327 (AGE) and recent developments in pharmaceuticals to reduce AGE accumulation. *Curr*
328 *Med Chem*. 2004; 11(20):2767-2784.
- 329 11. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic
330 mechanisms to clinical implications. *Atherosclerosis*. 2008; 196(1):9-21.
- 331 12. Sell DR, Monnier VM. Molecular basis of arterial stiffening: role of glycation - a
332 mini-review. *Gerontology*. 2012; 58(3):227-237.
- 333 13. Blair SN, Kampert JB, Kohl HW, 3rd, et al. Influences of cardiorespiratory fitness and
334 other precursors on cardiovascular disease and all-cause mortality in men and women.
335 *JAMA*. 1996; 276(3):205-210.
- 336 14. Maessen MF, Verbeek AL, Bakker EA, et al. Lifelong Exercise Patterns and
337 Cardiovascular Health. *Mayo Clin Proc*. 2016; 91(6):745-754.
- 338 15. Eijssvogels TM, Molossi S, Lee DC, et al. Exercise at the Extremes: The Amount of
339 Exercise to Reduce Cardiovascular Events. *J Am Coll Cardiol*. 2016; 67(3):316-329.
- 340 16. Mora S, Cook N, Buring JE, et al. Physical activity and reduced risk of cardiovascular
341 events: potential mediating mechanisms. *Circulation*. 2007; 116(19):2110-2118.
- 342 17. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. *Cochrane*
343 *Database Syst Rev*. 2006(3):CD002968.
- 344 18. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of
345 exercise on plasma lipoproteins. *N Engl J Med*. 2002; 347(19):1483-1492.

19. Ito D, Cao P, Kakihana T, et al. Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats. *PLoS One*. 2015; 10(9):e0138037.
20. Boor P, Celec P, Behuliak M, et al. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. *Metabolism*. 2009; 58(11):1669-1677.
21. Macias-Cervantes MH, Rodriguez-Soto JM, Uribarri J, et al. Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men. *Nutrition*. 2015; 31(3):446-451.
22. Oudegeest-Sander MH, Olde Rikkert MG, Smits P, et al. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial. *Exp Gerontol*. 2013; 48(12):1509-1517.
23. Goon JA, Aini AH, Musalmah M, et al. Effect of Tai Chi exercise on DNA damage, antioxidant enzymes, and oxidative stress in middle-age adults. *J Phys Act Health*. 2009; 6(1):43-54.
24. Balady GJ, Arena R, Sietsema K, et al. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. *Circulation*. 2010; 122(2):191-225.
25. Edvardsen E, Hem E, Anderssen SA. End criteria for reaching maximal oxygen uptake must be strict and adjusted to sex and age: a cross-sectional study. *PLoS One*. 2014; 9(1):e85276.
26. Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 Compendium of Physical Activities: a second update of codes and MET values. *Med Sci Sports Exerc*. 2011; 43(8):1575-1581.

- 371 27. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial
372 stiffness: methodological issues and clinical applications. *Eur Heart J.* 2006;
373 27(21):2588-2605.
- 374 28. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin
375 resistance and beta-cell function from fasting plasma glucose and insulin
376 concentrations in man. *Diabetologia.* 1985; 28(7):412-419.
- 377 29. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile
378 for use in primary care: the Framingham Heart Study. *Circulation.* 2008; 117(6):743-
379 753.
- 380 30. Hanssen NM, Engelen L, Ferreira I, et al. Plasma levels of advanced glycation
381 endproducts Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine, and
382 pentosidine are not independently associated with cardiovascular disease in
383 individuals with or without type 2 diabetes: the Hoorn and CODAM studies. *J Clin*
384 *Endocrinol Metab.* 2013; 98(8):E1369-1373.
- 385 31. Scheijen JL, van de Waarenburg MP, Stehouwer CD, et al. Measurement of
386 pentosidine in human plasma protein by a single-column high-performance liquid
387 chromatography method with fluorescence detection. *J Chromatogr B Analyt Technol*
388 *Biomed Life Sci.* 2009; 877(7):610-614.
- 389 32. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-
390 deoxyglucosone in the glycation of proteins by glucose. *Biochem J.* 1999; 344 Pt
391 1:109-116.
- 392 33. Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins
393 and nucleic acids, and enzymatic detoxification-a role in pathogenesis and
394 antiproliferative chemotherapy. *Gen Pharmacol.* 1996; 27(4):565-573.

34. Dieter BP, Vella CA. A proposed mechanism for exercise attenuated methylglyoxal accumulation: activation of the ARE-Nrf pathway and increased glutathione biosynthesis. *Med Hypotheses*. 2013; 81(5):813-815.
35. Ahmed N, Argirov OK, Minhas HS, et al. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modified albumin. *Biochem J*. 2002; 364(Pt 1):1-14.
36. Coupe C, Svensson RB, Grosset JF, et al. Life-long endurance running is associated with reduced glycation and mechanical stress in connective tissue. *Age (Dordr)*. 2014; 36(4):9665.
37. Ziemann SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. *Arterioscler Thromb Vasc Biol*. 2005; 25(5):932-943.
38. Gu Q, Wang B, Zhang XF, et al. Contribution of receptor for advanced glycation end products to vasculature-protecting effects of exercise training in aged rats. *Eur J Pharmacol*. 2014; 741:186-194.
39. Gaens KH, Goossens GH, Niessen PM, et al. Nepsilon-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. *Arterioscler Thromb Vasc Biol*. 2014; 34(6):1199-1208.
40. Powers SK, Jackson MJ. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. *Physiol Rev*. 2008; 88(4):1243-1276.
41. Anderson MM, Heinecke JW. Production of N(epsilon)-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants

419 in the formation of advanced glycation end products during inflammation. *Diabetes*.
420 2003; 52(8):2137-2143.

421 42. Fisher-Wellman K, Bloomer RJ. Acute exercise and oxidative stress: a 30 year
422 history. *Dyn Med*. 2009; 8:1.

423 43. Poulsen MW, Hedegaard RV, Andersen JM, et al. Advanced glycation endproducts in
424 food and their effects on health. *Food Chem Toxicol*. 2013; 60:10-37.

425

426 **Figure legend**

Figure 1. Individual and average values of markers for (A) dicarbonyl stress and (B) advanced glycation endproducts in lifelong athletes (circles) and sedentary controls (squares). For dicarbonyl markers, GO concentrations did not differ between groups, whereas MGO and 3DG were significantly lower in athletes compared to controls. For advanced glycation endproducts, CML and CEL concentrations were higher in athletes compared to controls. Concentrations of pentosidine did not differ between groups. Concentrations of MG-H1 were lower in athletes compared to controls. P-value refers to an *independent Student's t* or (¥) *Mann-Whitney U* test. Group averages are presented as median and interquartile range.

427

Table 1. Participants' characteristics of lifelong endurance athletes (ATH, $n=18$) and sedentary controls (SED, $n=18$). Data is presented as mean and standard deviation or median and interquartile range (IQR). P-value refers to an *independent Student's t* test or *Mann-Whitney U* (*) test.

n	ATH 18	SED 18	p -value
CHARACTERISTICS			
Age (years)	61 \pm 7	58 \pm 7	0.29
Height (m)	179 \pm 8	181 \pm 6	0.31
Weight (kg)	74 \pm 8	87 \pm 10	<0.01
Body Mass Index (kg/m ²) ¥	23.6 (21.1-24.9)	26.7 (25.0-27.4)	<0.01
Mean arterial pressure (mmHg) *	98 (90-106)	103 (93-107)	0.70
Systolic blood pressure (mmHg)	134 \pm 17	137 \pm 16	0.53
Diastolic blood pressure (mmHg)	84 \pm 10	84 \pm 10	0.92
Smoking history (%yes [n])	10 (56)	15 (83)	0.15
CARDIOVASCULAR HEALTH PARAMETERS			
Pulse Wave Velocity			
Central PWV (m/s)	7.0 \pm 2.2	9.2 \pm 2.3	<0.01
Peripheral PWV (m/s)	8.1 \pm 1.5	9.4 \pm 1.6	0.017
Framingham Risk Score (%) *	10.1 (7.5-20.3)	16.5 (10.1-19.5)	0.12
VO ₂ peak (mL/min)	3544 \pm 651	2843 \pm 519	<0.01
Fasting blood levels			
HbA1c (mmol/mol) ¥	35.5 (34.4-38.3)	35.5 (35.5-38.3)	0.53
Cholesterol (mmol/L)	5.4 \pm 0.8	5.9 \pm 0.9	0.07
LDL (mmol/L)	3.3 \pm 0.8	4.0 \pm 0.8	0.012
HDL (mmol/L)	1.8 \pm 0.3	1.4 \pm 0.3	<0.01
Triglycerides (mmol/L) *	0.8 (0.7-1.2)	1.3 (1.0-2.4)	<0.01
Glucose (mmol/L) *	4.6 (4.4-5.0)	4.7 (4.4-4.9)	0.66
Insulin (mU/L)	2.8 \pm 1.8	6.8 \pm 2.9	<0.01
HOMA-IR *	0.5 (0.3-0.9)	1.3 (0.8-2.2)	<0.01
LIFELONG EXERCISE PATTERNS			
Exercise time (hours/week) ¥	7.1 (5.8-11.9)	0.5 (0.0-1.4)	<0.01
Exercise dose (MET-hours/week) ¥	60 (47-110)	4 (0-12)	<0.01
INCREMENTAL EXERCISE TEST			
Maximal heart rate (beats/min)	165 \pm 13	171 \pm 15	0.29
RER (ratio: VCO ₂ / VO ₂) *	1.13 (1.06-1.17)	1.08 (1.05-1.14)	0.029
Lactate (mmol/L) *	11.6 (8.9-12.3)	11.1 (9.4-12.8)	0.77
Power Output (W)	319 \pm 58	209 \pm 46	<0.01

HbA1c: Glycated haemoglobin; HDL: High-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; LDL: low-density lipoprotein; MET: Metabolic Equivalent of Task; PWV: pulse wave velocity; RER: respiratory exchange ratio; VO₂peak: peak oxygen uptake;

* Data were log_e-transformed before statistical analysis

¥ non-parametrically tested via Mann-Whitney U


Table 2. *Spearman's Rank (ρ) correlations between dicarbonyl stress, advanced glycation endproducts, and cardiovascular health parameters*

	Dicarbonyl stress			Advanced glycation endproducts			
	GO	MGO	3DG	CML	CEL	Pentosidine	MG-H1
CARDIOVASCULAR HEALTH MARKERS							
BMI	0.02	0.35*	0.40*	-0.53**	-0.13	-0.31	0.19
Average PWV	0.12	0.35*	0.55**	-0.54**	0.10	-0.31	0.04
Central PWV	0.24	0.51**	0.46**	-0.30	0.07	-0.10	0.03
Peripheral PWV	-0.05	0.10	0.44**	-0.58**	0.11	-0.43*	0.02
VO ₂ peak (mL/min)	0.01	-0.32	-0.47**	0.34*	0.33	0.18	-0.55**
FRS	0.24	0.52**	0.43**	-0.23	-0.06	-0.09	0.11
Glucose	-0.19	0.15	0.46**	-0.13	0.13	-0.41*	-0.09
Insulin	0.04	0.36*	0.44**	-0.36*	-0.24	-0.12	0.35*
HOMA-IR	-0.01	0.34	0.49**	-0.36*	-0.21	-0.16	0.33
LIFELONG EXERCISE PATTERNS							
Exercise time	-0.04	-0.34*	-0.53**	0.46**	0.32	0.28	-0.36*
Exercise dose	-0.04	-0.34*	-0.53**	0.45**	0.36*	0.30	-0.37*

3DG: 3-deoxyglucosone; CEL: N ϵ -(carboxyethyl)lysine; CML: N ϵ -(carboxymethyl)lysine; FRS: Framingham risk score; GO: glyoxal; HOMA-IR: homeostasis model assessment of insulin resistance; MG-H1: Methylglyoxal-derived hydroimidazolone-1; MGO: methylglyoxal; VO₂peak: peak oxygen uptake (cardiorespiratory fitness); Average PWV: average pulse wave velocity, the average of the z-scores of central and peripheral PWV; Correlation is significant at *0.05 or **0.01 level (two-sided).

Figure_1

A. Markers for dicarbonyl stress



B. Markers for advanced glycation endproducts

